Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Clinical trial NCT02139592 · COMPLETED
Trial details
- NCT number
- NCT02139592
- Sponsor
- Takeda
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2014-04-17
- Primary completion
- 2017-06-30
- Enrollment
- 292
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.